Clinical Trial Update: The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing switching to flumatinib versus continuing dasatinib after imatinib-related low-grade adverse events in chronic myeloid leukemia in chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia in Chronic Phase

Drugs mentioned

• DASATINIB (Dasatinib)
• Flumatinib (flumatinib)
• Imatinib (imatinib)

Snippet

Sponsor: Shenzhen Second People's Hospital | Conditions: Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Status: UNKNOWN